What did ICRA announce about Natco Pharma's credit rating?

ICRA Limited has reaffirmed and assigned credit ratings for Natco Pharma's various debt instruments.

How did Natco Pharma's stock react to the credit rating news?

Natco Pharma's share price surged by 5% on the BSE following the announcement of its reaffirmed credit ratings.

What are Natco Pharma's key financial metrics?

Natco Pharma reported a trailing twelve-month EPS of 85.79, CEPS of 100.04, PE ratio of 10.66, ROE of 22.18, and PB ratio of 2.39.

Home / Business and Economy / Natco Pharma's Credit Rating Affirmed by ICRA

Natco Pharma's Credit Rating Affirmed by ICRA

2 Dec, 2025

•

Summary

Natco Pharma's debt instruments received reaffirmed credit ratings from ICRA.
The company's stock price saw a 5% surge following the rating announcement.
Natco Pharma's market capitalization reached ₹16,378.70 crore on BSE.

Natco Pharma's Credit Rating Affirmed by ICRA

ICRA Limited has reaffirmed and assigned credit ratings to Natco Pharma's diverse debt instruments, according to a recent regulatory filing. The ratings agency has confirmed the long-term and short-term fund-based working capital limits at [ICRA]AA (Stable)/[ICRA]A1+, alongside similar affirmations for non-fund based working capital limits. This assessment reflects confidence in the company's financial stability and operational capabilities.

Following this news, Natco Pharma's shares experienced a notable uptick, rising 5% to ₹922.15 on the BSE on December 1, 2025. The pharmaceutical counter attracted considerable buying interest, with nearly 3 million equity shares trading hands by midday, indicating positive investor sentiment. The company's market capitalization was reported at ₹16,378.70 crore.